Loading...
XNAS
INDV
Market cap2.13bUSD
Jul 11, Last price  
15.47USD
1D
0.65%
1Q
69.81%
IPO
-32.06%
Name

Indivior PLC

Chart & Performance

D1W1MN
P/E
1,066.49
P/S
1.80
EPS
0.01
Div Yield, %
Shrs. gr., 5y
-2.52%
Rev. gr., 5y
7.82%
Revenues
1.19b
+8.69%
968,885,4631,148,105,410959,924,667815,158,372689,681,478777,481,856884,629,7551,093,000,0001,188,000,000
Net income
2m
0.00%
32,051,97660,924,166262,665,953139,148,053-157,763,305205,000,000-52,037,0442,000,0002,000,000
CFO
36m
P
372,718,699309,872,914289,410,123156,801,164-205,731,878346,967,250-3,927,324-315,000,00036,000,000
Earnings
Jul 23, 2025

Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
IPO date
Dec 23, 2014
Employees
1,000
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
1,188,000
8.69%
1,093,000
23.55%
884,630
13.78%
Cost of revenue
956,000
1,103,000
1,002,567
Unusual Expense (Income)
NOPBT
232,000
(10,000)
(117,937)
NOPBT Margin
19.53%
Operating Taxes
11,000
(1,000)
(41,237)
Tax Rate
4.74%
NOPAT
221,000
(9,000)
(76,700)
Net income
2,000
0.00%
2,000
-103.84%
(52,037)
-125.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
(170,000)
(29,000)
(86,401)
BB yield
Debt
Debt current
38,000
12,000
11,059
Long-term debt
74,000
313,000
267,437
Deferred revenue
Other long-term liabilities
696,000
378,084
464,496
Net debt
(235,000)
(125,809)
(717,858)
Cash flow
Cash from operating activities
36,000
(315,000)
(3,927)
CAPEX
(29,000)
(8,000)
(5,891)
Cash from investing activities
69,000
(100,361)
(218,948)
Cash from financing activities
(102,000)
(46,000)
(98,183)
FCF
243,652
(30,193)
(67,345)
Balance
Cash
320,000
410,000
897,825
Long term investments
27,000
40,809
98,530
Excess cash
287,600
396,159
952,123
Stockholders' equity
(428,000)
(9,132)
43,232
Invested Capital
846,000
671,975
712,831
ROIC
29.12%
ROCE
55.50%
EV
Common stock shares outstanding
133,000
141,800
139,012
Price
Market cap
EV
EBITDA
261,000
18,675
(97,319)
EV/EBITDA
Interest
41,000
37,000
29,000
Interest/NOPBT
17.67%